ABSTRACT
Pediatric observation units (OUs) are hospital areas used to provide medical evaluation and/or management for health-related conditions in children, typically for a well-defined, brief period. Pediatric OUs represent an emerging alternative site of care for selected groups of children who historically may have received their treatment in an ambulatory setting, emergency department, or hospital-based inpatient unit. This clinical report provides an overview of pediatric OUs, including the definitions and operating characteristics of different types of OUs, quality considerations and coding for observation services, and the effect of OUs on inpatient hospital utilization.
Subject(s)
Delivery of Health Care/methods , Hospital Units/organization & administration , Pediatrics , Child , Hospitalization , Humans , Quality Assurance, Health Care , United StatesSubject(s)
Clinical Competence/standards , Competency-Based Education/methods , Hospitalists/education , Hospitals, Pediatric/standards , Pediatrics/education , Adolescent , Child , Child, Preschool , Competency-Based Education/standards , Curriculum/standards , Curriculum/trends , Hospitalists/standards , Humans , Infant , Infant, Newborn , Pediatrics/methods , Pediatrics/standards , WorkforceABSTRACT
Systemic-onset juvenile idiopathic arthritis (SoJIA) accounts for a relatively small proportion of patients with juvenile arthritis. Its clinical manifestations are unique among the subsets of JIA and studies of cytokine profiles suggest differences between the underlying mechanisms of the different diseases. SoJIA may, in fact, be better classified separately from other subtypes of JIA. New biologic agents that are currently licensed or being tested, target the cytokines interleukin-1 and interleukin-6 and appear to be effective in treating SoJIA. By contrast, anti-tumor necrosis factor therapy is much less, if at all, successful in this subgroup of JIA. This article reviews the current literature on the pathogenesis and treatment of SoJIA.
ABSTRACT
A 3-year-old patient with biopsy-proven herpesvirus 6 (HHV-6) encephalitis developed a clinical condition consistent with systemic-onset juvenile idiopathic rheumatoid arthritis (SoJIA) and responsive to synthetic interleukin-1 (IL-1) receptor therapy. This suggested both a temporal relationship between HHV-6 infection and the development of SoJIA and the likely involvement of IL-1 in his disease. This case adds to the current experience of IL-1 receptor antagonist therapy in SoJIA. In addition, it suggests that future prospective studies in new-onset SoJIA should include an evaluation for HHV-6 infection.
Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Juvenile/drug therapy , Arthritis, Juvenile/virology , Roseolovirus Infections/complications , Sialoglycoproteins/therapeutic use , Antiviral Agents/therapeutic use , Child, Preschool , Encephalitis, Viral/drug therapy , Encephalitis, Viral/virology , Fever/drug therapy , Fever/virology , Ganciclovir/therapeutic use , Herpesvirus 6, Human/isolation & purification , Humans , Interleukin 1 Receptor Antagonist Protein , Male , Receptors, Interleukin-1/antagonists & inhibitors , Roseolovirus Infections/drug therapySubject(s)
Arthritis, Juvenile/complications , Klinefelter Syndrome/complications , Adolescent , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Arthritis, Juvenile/drug therapy , Arthritis, Juvenile/physiopathology , Humans , Klinefelter Syndrome/diagnosis , Klinefelter Syndrome/physiopathology , Male , Methotrexate/therapeutic use , Treatment OutcomeSubject(s)
Anticoagulants/poisoning , Arthritis, Juvenile/diagnosis , Kidney/injuries , Low Back Pain/etiology , Vitamin K Deficiency/diagnosis , Warfarin/poisoning , Child , Diagnosis, Differential , Epistaxis/etiology , Female , Hematuria/etiology , Humans , Infant , Male , Prognosis , Urinalysis , Vitamin K Deficiency/etiologyABSTRACT
BACKGROUND: In May 1996, the CDC recommended obtaining a complete blood count and blood culture (BC) from all asymptomatic "at risk" newborns; those > or =35 weeks gestation born to mothers with group B streptococcal vaginal colonization or those with maternal fever, premature rupture of membranes or previous infant with group B streptococcal disease; who did not receive adequate intrapartum antibiotic prophylaxis. DESIGN/METHODS: During the study period (May 1996 to July 1999), a complete blood count and BC were obtained within 4 h from all asymptomatic at risk newborns of > or =35 weeks gestation. White blood cell count (WBC) and BC results and prevalence of clinical or culture-proven sepsis were obtained by chart review. We determined the sensitivity/specificity and likelihood ratios of an abnormal WBC (total >30 000 or <5000/mm3; absolute neutrophil count <1500/mm3, or a band form-polymorphonuclear cell ratio of >0.2) to distinguish between clinically septic vs. nonseptic term at risk newborns. RESULTS: Of 20 554 deliveries 1665 were initially asymptomatic at risk newborns; 17 (1.0%) developed early onset sepsis, all within 48 h. WBC was abnormal in 7 of 17 (41%) and in 447 of 1648 (27%) who remained nonseptic. None of the 1665 term at risk newborns had a positive BC. The sensitivity and specificity of an abnormal WBC in predicting which at risk newborns would develop sepsis were 41 and 73%, respectively. The positive likelihood ratio was 1.52, whereas the negative likelihood ratio was 0.81, with an odds ratio of 1.88. CONCLUSIONS: Since the implementation of the CDC guidelines for maternal intrapartum antibiotic prophylaxis, culture-proved sepsis has become rare at our institution. Although BC did not aid in the diagnosis of sepsis among asymptomatic at risk newborns, close observation in the first 24 h remained critically important.